Published 2 months ago

Anocca AB Licenses Gene Editing Technology from EmendoBio Inc.

Summary by Ground News

Anocca AB and EmendoBio announce a non-exclusive licensing agreement for the use of Emendo's novel OMNI-A4 nuclease. The technology will accelerate the manufacture and development of Anocca's TCR-T cell therapies for difficult-to-treat solid cancers.

0 Articles

All

Left

Center

Right

Benzinga

Anocca AB Licenses Gene Editing Technology from EmendoBio Inc.

NEW YORK and SÖDERTÄLJE, Sweden, March 14, 2024 (GLOBE NEWSWIRE) -- Anocca AB (Anocca), a leading T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, and EmendoBio Inc. (EmendoBio), a nuclease discovery and gene editing therapeutics company, today announced a non-exclusive licensing agreement for the use of EmendoBio's novel OMNI-A4 nuclease to accelerate the manufacture and development of Anocca's deep pipeline of TCR-T c…

2 months ago·New York, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.